These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 17287964)

  • 1. [Therapy of follicular lymphoma].
    Buske C; Unterhalt M; Hiddeman W
    Internist (Berl); 2007 Apr; 48(4):372-81. PubMed ID: 17287964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapy of mantle cell lymphoma].
    Dreyling M; Unterhalt M; Weigert O; Hiddemann W
    Internist (Berl); 2007 Apr; 48(4):382-8. PubMed ID: 17308912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial.
    Morschhauser F; Radford J; Van Hoof A; Botto B; Rohatiner AZ; Salles G; Soubeyran P; Tilly H; Bischof-Delaloye A; van Putten WL; Kylstra JW; Hagenbeek A
    J Clin Oncol; 2013 Jun; 31(16):1977-83. PubMed ID: 23547079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
    J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.
    Witzig TE; Flinn IW; Gordon LI; Emmanouilides C; Czuczman MS; Saleh MN; Cripe L; Wiseman G; Olejnik T; Multani PS; White CA
    J Clin Oncol; 2002 Aug; 20(15):3262-9. PubMed ID: 12149300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshop.
    Zinzani PL; d'Amore F; Bombardieri E; Brammer C; Codina JG; Illidge T; Jurczak W; Linkesch W; Morschhauser F; Vandenberghe E; Van Hoof A
    Eur J Cancer; 2008 Feb; 44(3):366-73. PubMed ID: 18194857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Monoclonal antibody treatment of malignant lymphoma].
    Buske C; Dreyling M; Unterhalt M; Hiddemann W
    Internist (Berl); 2004 Dec; 45(12):1370-7. PubMed ID: 15517123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.
    Morschhauser F; Radford J; Van Hoof A; Vitolo U; Soubeyran P; Tilly H; Huijgens PC; Kolstad A; d'Amore F; Gonzalez Diaz M; Petrini M; Sebban C; Zinzani PL; van Oers MH; van Putten W; Bischof-Delaloye A; Rohatiner A; Salles G; Kuhlmann J; Hagenbeek A
    J Clin Oncol; 2008 Nov; 26(32):5156-64. PubMed ID: 18854568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How have outcomes for patients with follicular lymphoma changed with the addition of monoclonal antibodies?
    Illidge T; Chan C
    Leuk Lymphoma; 2008 Jul; 49(7):1263-73. PubMed ID: 18604715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transplantation strategies for patients with follicular lymphoma.
    Buske C; Dreyling M; Unterhalt M; Hiddemann W
    Curr Opin Hematol; 2005 Jul; 12(4):266-72. PubMed ID: 15928482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current management of follicular lymphomas.
    Hiddemann W; Buske C; Dreyling M; Weigert O; Lenz G; Unterhalt M
    Br J Haematol; 2007 Jan; 136(2):191-202. PubMed ID: 17073892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management options for follicular lymphoma: observe; R-CHOP; B-R; others?
    McLaughlin P
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S91-5. PubMed ID: 22035757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of aggressive lymphomas].
    Gleissner B; Zwick C; Pfreundschuh M
    Internist (Berl); 2007 Apr; 48(4):389-95. PubMed ID: 17361405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioimmunotherapy in follicular lymphoma: some like it hot….
    Kersten MJ
    Transfus Apher Sci; 2011 Apr; 44(2):173-8. PubMed ID: 21334979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular lymphoma: a Wisconsin Oncology Network study.
    Rajguru S; Kristinsdottir T; Eickhoff J; Peterson C; Meyer CM; Traynor AM; Kahl BS
    Clin Adv Hematol Oncol; 2014 Aug; 12(8):509-15. PubMed ID: 25356575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma.
    Marcus R
    Semin Oncol; 2005 Feb; 32(1 Suppl 1):S36-43. PubMed ID: 15786024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigational strategies in autologous stem cell transplantation for follicular lymphoma.
    Weigert O; Dreyling M; Unterhalt M; Hiddemann W; Buske C
    Curr Oncol Rep; 2006 Sep; 8(5):368-75. PubMed ID: 16901398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue.
    Hohloch K; Sahlmann CO; Lakhani VJ; Wulf G; Glass B; Hasenkamp J; Meller J; Riggert J; Trümper L; Griesinger F
    Ann Hematol; 2011 Nov; 90(11):1307-15. PubMed ID: 21360108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioimmunotherapy for B-cell non-Hodgkin lymphoma.
    Witzig TE
    Best Pract Res Clin Haematol; 2006; 19(4):655-68. PubMed ID: 16997175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of ibritumomab tiuxetan radioimmunotherapy for patients with relapsed B-cell non-Hodgkin's lymphoma.
    Witzig TE
    Semin Oncol; 2000 Dec; 27(6 Suppl 12):74-8. PubMed ID: 11226003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.